Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

This study found that several newly synthesized dihydrobenzopyran compounds inhibited insulin secretion and had vasorelaxant activity, with some more potent than reference KATP channel activators, though compound 21 functioned as a Ca2+ entry blocker.

This study found that testosterone administration reduced the expression of uterine receptivity molecules in ovariectomized rats, which may negatively affect early pregnancy establishment and female fertility.

This review focuses on the immunologic-based skin conditions that can result from β-blocker use, emphasizing potential adverse dermatologic effects rather than their therapeutic benefits.

Adding diltiazem to a beta blocker can cause dangerously slow heart rates.

This study outlines new strategies for overcoming "cold" tumors, which are typically unresponsive to cancer immunotherapy, with approaches like dendritic cell-based treatments and local immune microenvironment modification, bolstered by both preclinical and clinical trial data.

This study found that cucurbitacin I from bitter melon most effectively inhibited the growth of lung cancer cells and promoted hair cell growth in cell cultures.

This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Doxazosin and finasteride negatively affect sexual function in men with BPH.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This article reviews the use of cross-sex hormonal therapy in transmen and reports that it is reasonably safe, suggesting monitoring should be frequent initially but can be less frequent over time.

This article reviews endocrine therapies for androgen excess disorders, emphasizing spironolactone, estrogen, and dexamethasone as effective treatments; it reports no new clinical results.

This report describes a case in which the use of the beta-blocker nadolol was associated with infiltrative dermatitis and significant alopecia, which resolved and resulted in total hair regrowth after discontinuation of the drug.

This review discusses the effects of hormonal treatments on the physical and mental health of transgender individuals, reporting significant reductions in mental health issues following treatment, but calls for more research on long-term and nonbinary outcomes.

This article suggests that modern lifestyle changes, including diet, stress, and chronic anti-inflammatory medication use, may disrupt the natural process of inflammation resolution, increasing vulnerability to chronic disease.

This study reported that treatment with gonadotropin-releasing hormone analogs and cross-sex hormones appears appropriate for carefully selected youth with gender dysphoria, but long-term safety needs further investigation.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This study found that human hair follicles express ATP-sensitive potassium channels, suggesting that minoxidil acts on these channels and that drugs targeting them may treat hair disorders.

This article outlines the clinical features, evaluation, and treatment strategies for androgen excess in polycystic ovary syndrome, highlighting important diagnostic and management approaches but reporting no new research results.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This review offers transgender hormone treatment guidelines to assist healthcare providers in improving transgender patients' access to and outcomes of medical care, but it reports no new clinical results.

This study suggests that CD8+ cytotoxic T lymphocytes play a crucial role in the development of alopecia areata, based on observations in rodent models that mimic human autoimmune disease.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.